|Bid||6.75 x 10000|
|Ask||11.95 x 300|
|Day's Range||8.30 - 8.52|
|52 Week Range||5.50 - 14.60|
|PE Ratio (TTM)||-3.63|
|Earnings Date||Aug 2, 2017 - Aug 7, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||25.50|
NEW YORK, May 18, 2017-- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet medical need, announced today that SL-401 ...
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Stemline Therapeutics Inc. into potential breaches of fiduciary duty by the Company’s Board of Directors .
The New York-based company said it had a loss of 67 cents per share. The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...